Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasm Metastasis × enzalutamide × Clear all

Phase

Status

Completed 7 Terminated 5 Recruiting 3 Unknown 2 Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 4 Prostatic Neoplasms, Castration-Resistant 2 Neoplasms 2 Neoplasm Metastasis 1 Breast Neoplasms 1

Interventions

Oxaliplatin 7 Radiosurgery 6 Docetaxel 6 Paclitaxel 5 Fluorouracil 5 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Trastuzumab 3 Radiotherapy 3 Radiation 3 Leucovorin 3 Gemcitabine 3 Cyclophosphamide 3 Capecitabine 3 Bevacizumab 3 spartalizumab 2 sipuleucel-T 2 repotrectinib 2 pembrolizumab 2 pazopanib 2 orteronel 2 fludarabine 2 atezolizumab 2 aldesleukin 2 Surveys and Questionnaires 2 Sunitinib 2 Specimen Handling 2 Neoadjuvant Therapy 2 Metformin 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02929576 2018-10-22

ENDEAR

Pfizer

Phase 3 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡